Related Experiment Video
Updated: Mar 1, 2026
Transcutaneous Microcirculatory Imaging in Preterm Neonates
Published on: December 31, 2015
Current screening and treatments in retinopathy of prematurity in the US
Ana M Suelves1, Julia P Shulman1
1Department of Ophthalmology, New York Medical College, Valhalla, NY, USA.
Insights
Retinopathy of prematurity (ROP) is a serious eye condition in preterm infants. This review details current US guidelines for ROP screening, diagnosis, and treatment to improve infant vision outcomes.
Area of Science:
- Ophthalmology
- Neonatology
- Developmental Biology
Background:
- Retinopathy of prematurity (ROP) is a leading cause of visual impairment in premature infants.
- Aberrant retinal angiogenesis in ROP can lead to severe vision loss, including blindness.
- Despite advances, ROP management remains challenging for clinicians.
Purpose of the Study:
- To provide an up-to-date review of screening protocols for ROP in the US.
- To outline current diagnostic criteria and approaches for ROP.
- To summarize evidence-based treatment guidelines for ROP management.
Main Methods:
- Literature review of recent randomized clinical trials and guidelines.
- Synthesis of current screening, diagnostic, and treatment strategies.
- Focus on US-based recommendations and practices.
Main Results:
- Established screening criteria for premature infants at risk of ROP.
- Detailed diagnostic methods including funduscopic examination and imaging.
- Summarized treatment options such as laser photocoagulation and anti-VEGF therapy.
Conclusions:
- Early screening and timely diagnosis are critical for preventing vision loss in ROP.
- Adherence to updated US guidelines can optimize ROP management.
- Ongoing research continues to refine ROP treatment strategies.
Abstract:
Retinopathy of prematurity (ROP) is a complex disease characterized by an aberrant developmental retinal angiogenesis in preterm infants and can carry significant visual morbidity, including retinal detachment and blindness. Though large scale, randomized clinical trials have improved our understanding of the pathophysiology and progression of the disease, the management of ROP remains a challenge for ophthalmologists. This review addresses the up-to-date screening approach, diagnosis, and treatment guidelines for ROP in the US.
